Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma
M. Lambropoulou1, G. Alexiadis2, V. Limberis3, N. Nikolettos4 and G. Tripsianis2
1Department of Pathology, Democritus University of Thrace, 2Department of Medical Statistics, Democritus University of Thrace, 3Department of Obstetrics and Gynecology, Democritus University of Thrace and 4Department of Physiology, Democritus University of Thrace
Offprint requests to: Dr. Maria Lambropoulou, Alamanas 25, 68100, Alexandroupolis, Greece. e-mail: alexrad@in.gr
Summary. Backgroud: Endometrial carcinoma is the most common malignancy of the female genital tract in the Western world. COX-2 is highly expressed in endometrial carcinoma, but there is controversy regarding its clinical role and its possible prognostic role. COX-2 expression was determined by immuno-histochemistry and was correlated to standard clinico-pathologic variables in a series of primary untreated endometrial carcinoma patients. COX-2 as an accurate predictor of the disease was also analyzed. Methods: One-hundred and ten cases of primary untreated endometrial carcinoma hosts who were admitted to the Department of Obstetrics and Gynecology, University General Hospital of Alexandroupolis, were investigated. Immunohistochemistry was performed using rabbit polyclonal antiserum against human COX-2. Results: Twenty-eight patients (25.5%) were scored as COX-2 positive. A statistically significant association was found between COX-2 overexpression and FIGO stage (p=0.010). A positive correlation was also found with histological grade (p=0.019) and myometrial invasion (p=0.026). No significant association was found with histologic type of the tumor (p=0.164). COX-2 positive patients had a significant association with sort survival (p=0.028). Conclusions: COX-2 expression is an independent clinicopathologic factor and an independent prognostic factor in endometrial carcinoma. It could be used to plan treatment modalities for hosts. Histol Histopathol 20, 753-759 (2005)
Key words: COX-2, Endometrial cancer, Immunohistochemistry
DOI: 10.14670/HH-20.753